G16B 20/30 - Détection de sites de liaison ou de motifs
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
3.
EXOSOMAL COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES
A61K 47/46 - Ingrédients de constitution indéterminée ou leurs produits de réaction, p. ex. peau, os, lait, fibre de coton, coquille d’œuf, fiel de bœuf ou extraits de plante
A61K 31/435 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
4.
METHOD AND APPARATUS FOR COLLECTING AND QUANTIFYING TONGUE MANIFESTATION FEATURES
A method for collecting and quantifying tongue manifestation features. The method comprises: first, automatically obtaining a high-quality tongue manifestation image that meets the requirements of traditional Chinese medicine tongue diagnosis; then, identifying from the image a tongue part of a patient, and acquiring an edge shape of a tongue surface, so as to obtain a tongue surface inspection area; performing color correction on the image by using the tongue surface inspection area, so as to subsequently perform, in the tongue surface inspection area, color and texture recognition on the tongue part; and further quantifying tongue color and tongue coating features. During remote consultation, traditional Chinese medicine physicians and/or traditional Chinese medicine practitioners can still perform tongue diagnosis, and it is possible to avoid misdiagnosis in remote diagnosis and treatment that is caused by differences in photography skills and photography device quality of patients, an insufficient capability for determining, when tongue manifestations are uploaded, whether the tongue manifestations meet the standards of traditional Chinese medicine diagnosis and treatment, etc.
A method of treating a glucose-6-phosphate dehydrogenase deregulated disorder in a subject in need thereof, the method involving administering a therapeutically effective amount of oleanolic acid or a conjugate salt thereof or prodrug thereof to the subject. The glucose-6-phosphate dehydrogenase deregulated disorder can be BCL2 associated athanogene myofibrillar myopathy, amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, or Alzheimer disease.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
6.
M-CELL GP2-MEDIATED LYMPHATIC-TARGETED DRUG CARRIERS
It provides a delivery agent including Radix Astragali polysaccharide (RAP) which modulates the immune system quickly and induces anti-cancer immune responses after oral administration or aerosol administration. Fluorescently labeled RAP is shown to be efficiently delivered to mucosa of small intestine or lung by transcytosis through microfold (M) cells and directly got into contact with follicle dendritic cells (FDCs) or lung dendritic cells. In addition, it is demonstrated that glycoprotein 2 (GP2) -deficient M cells fail to transport RAP and induce immune responses, suggesting GP2 of M cells is a specific transcytosis receptor of RAP. It also provides that immunomodulatory polysaccharides could be directly transported into the mucosal immune system by M cells in a GP2-dependent way. These lymphatic-targeted macromolecules are potential delivery agent of poorly bioavailable small molecules, drugs and vaccines, or alike, via oral or aerosol drug administration.
A61K 47/61 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique le composé organique macromoléculaire étant un polysaccharide ou l’un de ses dérivés
7.
M-CELL GP2-MEDIATED LYMPHATIC-TARGETED DRUG CARRIERS
It provides a delivery agent including Radix Astragali polysaccharide (RAP) which modulates the immune system quickly and induces anti-cancer immune responses after oral administration or aerosol administration. Fluorescently labeled RAP is shown to be efficiently delivered to mucosa of small intestine or lung by transcytosis through microfold (M) cells and directly got into contact with follicle dendritic cells (FDCs) or lung dendritic cells. In addition, it is demonstrated that glycoprotein 2 (GP2) -deficient M cells fail to transport RAP and induce immune responses, suggesting GP2 of M cells is a specific transcytosis receptor of RAP. It also provides that immunomodulatory polysaccharides could be directly transported into the mucosal immune system by M cells in a GP2-dependent way. These lymphatic-targeted macromolecules are potential delivery agent of poorly bioavailable small molecules, drugs and vaccines, or alike, via oral or aerosol drug administration.
A61K 47/61 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique le composé organique macromoléculaire étant un polysaccharide ou l’un de ses dérivés
Taxamairin analogs useful in the treatment of cancer, pharmaceutical compositions including the same, methods of use thereof, and methods of preparation are provided. An efficient and scalable semi-synthesis of taxamairin compounds and analogs thereof from readily available commercial starting materials is provided. The synthesis involves low cost and relatively non-toxic reagents and is capable of synthesizing taxamairin A and taxamairin B and analogs thereof on multi-gram scale in yields up 12%and 21%, respectively.
C07C 69/013 - Esters d'alcools dont le groupe hydroxyle estérifié est lié à un atome de carbone d'un cycle autre qu'un cycle aromatique à six chaînons
C07C 39/19 - Composés comportant au moins un groupe hydroxyle ou O-métal lié à un atome de carbone d'un cycle aromatique à six chaînons monocycliques avec une insaturation autre que celle du cycle aromatique contenant des liaisons doubles carbone-carbone sans liaison triple carbone-carbone
A resource-independent and cost-efficient antimicrobial susceptibility testing (AST) system or apparatus that can rapidly process a large number of samples. The AST system includes a barcode-like cell sensor based on an adaptive linear filter array for implementing a fully automatic and microscope-free method for counting a very small volume of cells in samples, wherein suspended cells are concentrated into microbars with various lengths proportional to the number of cells. The AST system also includes an on-chip culture that takes much less time than standard methods, thereby realizing a low-cost and resource-independent platform for portable AST, from which results can be obtained through a portable device such as a cell phone.
C12Q 1/18 - Test de l'activité antimicrobienne d'un matériau
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables
C12Q 1/20 - Test de l'activité antimicrobienne d'un matériau utilisant des milieux polyvalents
G01N 33/48 - Matériau biologique, p. ex. sang, urineHémocytomètres
23 22233 with a thickness ranging from approximately 60nm to 90 nm.The total thickness of the multi-layer thin film structure ranges from approximately 280nm to 400nm. The composite thin film has a high abrasion resistance, an excellent adhesiveness and consistent appearance color with bare metal substrate.
C23C 14/06 - Revêtement par évaporation sous vide, pulvérisation cathodique ou implantation d'ions du matériau composant le revêtement caractérisé par le matériau de revêtement
Provided herein are tuberculatin analogs that are useful as antivirals, such as anti-HIV, anti-coronaviral, anti-Ebola viral, and anti-influenza viral agents and methods of use thereof.
C07D 407/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
A61K 31/7028 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques
Provided herein is a method of authenticating using peptide markers found in edible bird's nest hydrolysate. The method can be used to authenticate edible bird's nest and related products and/or distinguish between white edible bird's nest and grass edible bird's nest.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 30/88 - Systèmes intégrés d'analyse, spécialement adaptés à cet effet, non couverts par un seul des groupes
13.
PEPTIDE MARKERS FOR AUTHENTICATING EJIAO AND RELATED GELATINS
Provided is a method for authenticating animal hide gelatins using peptide markers found in animal hide gelatin hydrolysates. The method can be used to authenticate animal hide gelatins derived from donkey hide, horse hide, pig hide, and cattle hide.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
G01N 27/62 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'ionisation des gaz, p. ex. des aérosolsRecherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant les décharges électriques, p. ex. l'émission cathodique
G01N 24/08 - Recherche ou analyse des matériaux par l'utilisation de la résonance magnétique nucléaire, de la résonance paramagnétique électronique ou d'autres effets de spin en utilisant la résonance magnétique nucléaire
14.
METHOD AND APPARATUSES FOR A MULTI-LAYERED OR MULTIFACETED SYSTEM FOR DEACTIVATING AIRBORNE PARTICLES
An assembly to inactivate microbes in air flowing there through comprising an indirect air flow pathway, wherein the indirect air flow pathway comprises micro structures, micro cilia or meshes; wherein in the indirect air flow pathway a plurality microbial deactivation apparatuses are disposed. The plurality microbial deactivation apparatuses comprise at least one UV radiation apparatus (130), at least one physical nanometal oxide or nanometal apparatus (140), at least one negative ion apparatus (120), at least one temperature raising apparatus, at least one chemical oxidizer apparatus (150) and at least one organic antimicrobial apparatus (160). The assembly is effective in deactivation and removal of airborne particles, microbes, nanoparticles, gaseous and toxins.
Provided is a platform technology to deliver RNA therapeutics into cells. It provides a system for delivery of RNA molecules for biomedical purposes. The modular protein-based system described allows for customization of protein modules to achieve specificity in cell-targeting, thus having the ability to be optimized for treating different diseases. Examples of types of diseases that could adopt this technology for treatment include cancer, neurodegenerative diseases and viral infection.
The present invention relates to a solid-state blended polymer system that has the property of tunable lasing wavelength through adjusting the blending ratio. It can be used for health monitoring, environmental monitoring sensor and tissue imaging. Current materials do not have the broad tunable range; from blue to infra-red across the optical range. By using the same two polymers, it is possible to produce laser emitting blue to red colour. It simplifies the design, eases multi-wavelength laser sensor system integration and therefore, making the production cost-effective.
H01S 5/12 - Structure ou forme du résonateur optique le résonateur ayant une structure périodique, p. ex. dans des lasers à rétroaction répartie [lasers DFB]
H01S 5/36 - Structure ou forme de la région activeMatériaux pour la région active comportant des matériaux organiques
C08L 61/02 - Polymères de condensation obtenus uniquement à partir d'aldéhydes ou de cétones
C08L 65/00 - Compositions contenant des composés macromoléculaires obtenus par des réactions créant une liaison carbone-carbone dans la chaîne principaleCompositions contenant des dérivés de tels polymères
Patentiflorin A analogs that are useful as antivirals, such as anti-HIV, anti-coronaviral, anti-Ebola viral, and anti-influenza viral agents and methods of use thereof.
A61K 31/34 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide
A61K 31/7028 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques
C07D 407/02 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles
C07H 15/252 - Radicaux naphtacène, p. ex. daunomycines, adriamycines
C07H 17/04 - Radicaux hétérocycliques contenant uniquement des atomes d'oxygène comme hétéro-atomes du cycle
Provided herein are compositions and methods useful for the analysis and authentication of polysaccharide-rich herbs, such as Dendrobium officinale, Radix Astragali, Radix Angelica Sinensis, and related herbal products.
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
HONG KONG BAPTIST UNIVERSITY (Chine)
UNIVERSITE DE STRASBOURG (France)
UNIVERSITE PARIS-SACLAY (France)
Inventeur(s)
Wong, Ka-Leung
Goetz, Joan
Charbonniere, Loic
Hildebrandt, Niko
Nonat, Aline
Charpentier, Cyrille
Cardoso Dos Santos, Marcelina
Cifliku, Vjona
Abrégé
The invention provides luminescent lanthanide nanoparticles having simultaneously an improved brightness and an increased lifetime of the excited-state. These nanoparticles comprise terbium ions and ions of a second lanthanide, preferentially europium, and are coated with molecules of chromophore ligand bonded to the surface of the nanoparticle. The ligand is an organic molecule comprising at least one chromophore radical of formula (I) or of formula (II): wherein R is selected from H, CN group or COOH group. The phosphorescence excited-state lifetime is improved by energy transfer from surface terbium ions to core ions of the second lanthanide. The nanoparticle may further comprise a carrier molecule of analytical interest covalently attached to at least one ligand molecule.
C09K 11/02 - Emploi de substances particulières comme liants, revêtements de particules ou milieux de suspension
C09K 11/85 - Substances luminescentes, p. ex. électroluminescentes, chimiluminescentes contenant des substances inorganiques luminescentes contenant des métaux des terres rares contenant des halogènes
20.
ULTRABRIGHT LUMINESCENT LANTHANIDE NANOPARTICLES COMPRISING TERBIUM, WITH LONGER EXCITED-STATE LIFETIME
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITE PARIS SUD (France)
HONG KONG BAPTIST UNIVERSITY (Chine)
Inventeur(s)
Wong, Ka-Leung
Goetz, Joan
Charbonniere, Loïc
Hildebrandt, Niko
Nonat, Aline
Charpentier, Cyrille
Cardoso Dos Santos, Marcelina
Cifliku, Vjona
Abrégé
The invention provides luminescent lanthanide nanoparticles having simultaneously an improved brightness and an increased lifetime of the excited-state. These nanoparticles comprise terbium ions and ions of a second lanthanide, preferentially europium, and are coated with molecules of chromophore ligand bonded to the surface of the nanoparticle. The ligand is an organic molecule comprising at least one chromophore radical of formula (I) or of formula (II): wherein R is selected from H, CN group or COOH group. The phosphorescence excited-state lifetime is improved by energy transfer from surface terbium ions to core ions of the second lanthanide. The nanoparticle may further comprise a carrier molecule of analytical interest covalently attached to at least one ligand molecule.
C09K 11/02 - Emploi de substances particulières comme liants, revêtements de particules ou milieux de suspension
C09K 11/85 - Substances luminescentes, p. ex. électroluminescentes, chimiluminescentes contenant des substances inorganiques luminescentes contenant des métaux des terres rares contenant des halogènes
21.
SAPPHIRE COATED SUBSTRATE WITH A FLEXIBLE, ANTI-SCRATCH AND MULTI-LAYER COATING
233, or a mixture thereof comprising a metal selected from Mg or Si or AF, or a metal oxide selected from Si oxide, Ti oxide, Cr oxide, Ni oxide, Ag oxide, or Zr oxide onto the two layers of different metal oxide, and wherein the top layer has a thickness ranging from 20 nm to 200 nm. Also disclosed a substrate.
Provided herein are are porphyrinato-lanthanide complexes useful as theranostic agents and methods of preparation and use thereof. The porphyrinato-lanthanide complexes are useful in the treatment and imaging of cancer.
The present disclosure relates to compounds useful in the treatment, imaging, and/or diagnosis of Epstein-Barr virus (EBV)-positive cells, such as cancer.
C07C 229/56 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone de cycles aromatiques à six chaînons du même squelette carboné avec des groupes amino et carboxyle liés à des atomes de carbone du même cycle aromatique à six chaînons non condensé avec des groupes amino et carboxyle liés en position ortho
C07C 15/52 - Hydrocarbures cycliques ne contenant que des cycles aromatiques à six chaînons en tant que partie cyclique substitués par des radicaux hydrocarbonés non saturés polycycliques non condensés contenant un groupe de formule
C07D 209/54 - Composés hétérocycliques contenant des cycles à cinq chaînons condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle condensés avec un carbocycle condensés en spiro
A61K 31/403 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil condensés avec des carbocycles, p. ex. carbazole
Cyclic peptide agonists toward human galanin receptor 2 (GalR2) and galanin receptor 3 (GalR3) based on hidden conformation of spexin solution structure for GalR2 and GalR3-related and spexin-deficient disorders are designed and synthesized. LH101, LH102, and LH101 (Ac) are potent spexin analogs with prolonged action, which can be used in the treatment of GalR2 and GalR3-related diseases and spexin-deficient disorders, such as obesity.
C07K 14/72 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des hormones
A61K 38/00 - Préparations médicinales contenant des peptides
G01N 33/566 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet utilisant un support spécifique ou des protéines réceptrices comme réactifs pour la formation de liaisons par ligand
26.
MULTIPLE SURFACES FOR PHYSICAL-TO-IMAGE/IMAGE-TO-PHYSICAL REGISTRATION AND IMAGE VERIFICATION
This invention is about a novel image registration. This rigid registration is based on multiple surfaces arranged in a 3D relationship in the Cartesian coordinate system through a fiducial marker. In comparison to surface-based registration, this registration process provides more accurate registration or requires a smaller fiducial marker for the same level of registration accuracy. Moreover, this fiducial marker enables measuring coordinates in the physical domain; therefore the registration error can be measured by comparing coordinates of specific points in both physical and virtual domains. This has a potential application in comparing the imaging physical-to-image (PI) or printing image-to-physical (IP) modalities, for example, to compare the accuracies of the 3D model created by computed tomography and optical scanners. Other potential application also includes assisting a surgical navigation in a dental implant placement. The proposed fiducial marker therefore has potential development in the application of virtual reality.
G06F 19/00 - Équipement ou méthodes de traitement de données ou de calcul numérique, spécialement adaptés à des applications spécifiques (spécialement adaptés à des fonctions spécifiques G06F 17/00;systèmes ou méthodes de traitement de données spécialement adaptés à des fins administratives, commerciales, financières, de gestion, de surveillance ou de prévision G06Q;informatique médicale G16H)
A method and apparatus of an eye gaze tracking system using a generic camera under normal environment are disclosed. The method and apparatus can tolerate large illumination changes and feature low cost and simple operation. A method and apparatus for detecting fatigue of a user are also disclosed, comprising the steps of: localizing of the user's face; representing the user face and extracting image features therefrom; aligning the user's face and tracking the user's face; and detecting the user fatigue.
A61B 5/18 - Dispositifs pour l'exécution des tests de capacité pour conducteurs de véhicules
G06K 9/78 - Combinaison de l'obtention de l'image et de fonctions de reconnaissance
G06K 9/46 - Extraction d'éléments ou de caractéristiques de l'image
G06K 9/62 - Méthodes ou dispositions pour la reconnaissance utilisant des moyens électroniques
A61B 3/113 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure objective, c.-à-d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient pour déterminer ou enregistrer le mouvement de l'œil
G06K 9/00 - Méthodes ou dispositions pour la lecture ou la reconnaissance de caractères imprimés ou écrits ou pour la reconnaissance de formes, p.ex. d'empreintes digitales
A skin-whitening and skin-protection composition that comprises stilbenoid (s) and/or stilbenoid-containing extract (s) obtained from Dendrobium plants, such as Dendrobium officinale and Dendrobium nobile for the management of melanogenesis, skin-darkening and skin-aging. More particularly, it relates to the usage of Dendrobium ingredients and stilbenoids to reduce the formation of melanin in melanocytes. It also relates to the usage of Dendrobium ingredients and stilbenoids to reduce the generation of reactive oxygen species and oxidative free radicals. The use of Dendrobium-derived extracts or ingredients or stilbenoids in the formulation of skin-protection, skin-whitening and/or anti-skin aging products. Compounds for use in preparation of a composition for treating, preventing, and/or delaying the progress of skin darkening or for use in skin-whitening and skin-protection which are synthesized from dihydro-resveratrol and the related synthesis method are also provided.
New anticancer and anti-obesity agents based on the cyclic peptide compounds are disclosed, and its preparation and application method for treating cancer and obesity diseases are also disclosed.
C07K 7/64 - Peptides cycliques ne comportant que des liaisons peptidiques normales
C07K 7/50 - Peptides cycliques contenant au moins une liaison peptidique anormale
C07C 229/28 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant saturé et contenant des cycles
C07C 229/46 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino ou carboxyle liés à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons du même squelette carboné
An anti-reflective coating comprising a topmost anti-reflective material layer comprising of sapphire or Al 2O 3, the one or more middle anti-reflective material layers, and a bottommost anti-reflective material layer deposited on top of the substrate, wherein the topmost anti-reflective material layer, the one or more middle anti-reflective material layers, and the bottommost anti-reflective material layer have alternatively higher and lower refractive indices in respect with each other. The anti-reflective coating on a substrate can form high anti-scratching.
Provided herein is a new generation of PDT agents based on porphyrin-lanthanide complexes with specific functional groups which can specifically localize on particular tumors, and their PDT processes can be monitored via NIR emission from erbium. In particular, provided herein is a multi-modal lanthanide-porphyrin PDT agent (Er-R3) that are capable of killing the bladder tumor cells selectivity via1O2 from porphyrin moiety and affording the fluorescence imaging simultaneously upon Er-R3 binding with the integrin αvβ3 isoform in bladder cancer cells.
The present invention relates to a group of derivatives synthesized based on the ent-kaurane diterpenoid flexicaulin A and the methods to synthesize such diterpenoid derivatives. In particular, the chemical entities of such synthetic diterpene compounds in the manufacture of a medicament is for the treatment of tumors or cancers.
A61K 31/357 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant plusieurs atomes d'oxygène dans le même cycle, p. ex. éthers en couronne, guanadrel
A61K 31/22 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides acycliques, p. ex. pravastatine
33.
LANTHANIDE TOOLBOX FOR MULTI-MODAL, NON-INVASIVE TUMOR SPECIFIC THERANOSTIC PRODRUGS
Provided are theranostic prodrugs with responsive signals in-vitro or in-vivo and uses thereof. Also provided are synthesized europium complexes for evaluating the binding with integrin αvβ3.
C07D 401/10 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
C07D 401/06 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
Provided are porphyrin small molecules substitutes designed and synthesized for bulk hetero junction (BHJ) organic solar cells (OSOs). Provided are synthesized materials with strong and ordered self-assembly property, leading to form bicontinuous, interpenetrating networks which are required for efficient charge separation and transport in organic solar cells. The power conversion efficiency (PCE) of the solar cells devices based on the embodiments have the highest PCE among the solution-processed BHJ solar cell based on porphyrin small molecules up to date.
C07D 487/22 - Composés hétérocycliques contenant des atomes d'azote comme uniques hétéro-atomes dans le système condensé, non prévus par les groupes dans lesquels le système condensé contient au moins quatre hétérocycles
C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou
C09K 11/06 - Substances luminescentes, p. ex. électroluminescentes, chimiluminescentes contenant des substances organiques luminescentes
A nanostructure for use in proliferation and differentiation of neural stem cells. And a method of proliferating and differentiating neural stem cells.
A method to transfer a layer of harder thin film substrate onto a softer, flexible substrate. In particular, the present invention provides a method to deposit a layer of sapphire thin film on to a softer and flexible substrate e.g. quartz, fused silica, silicon, glass, toughened glass, PET, polymers, plastics, paper and fabrics. This combination provides the hardness of sapphire thin film to softer flexible substrates.
It is provided a nucleus-permeable small-molecule inhibitor, L2P4 (where L2 is 4-(4-( Diethylamino)styryl)-N-carboxymethylpryidinium chloride and P4 is an amino acid sequence comprising CAhxYFMVFGGRrRK and they were coupled through amide bond) and synthesis thereof, which effectively targets the dimerization interface of EBNA1, a critical process for the growth of EBVs and the associated tumors. The method of treating and imaging EBV-associated cancers is also provided.
An apparatus for measuring balance ability; postural deviation, reflex and fall risk assessment of a human subject. In particular, the apparatus comprises of an elastic support mounted platform with dynamic response to external motion stimuli, an IMU and data analysis software processing device. The dynamic response from the platform also simulates realistic experience in moving over rough terrain with different topography.
A61B 5/103 - Dispositifs de mesure pour le contrôle de la forme, du dessin, de la dimension ou du mouvement du corps ou de parties de celui-ci, à des fins de diagnostic
39.
ANTI-CANCER COMPOSITION CONSISTING OF HALOFUGINONE AND SESQUITERPENE LACTONE COMPOUNDS OF ARTEMISIA APIACEA AND USE THEREOF
The invention provides an anti-cancer composition, wherein the active ingredients thereof consist of halofuginone and sesquiterpene lactone compounds of Artemisia apiacea. The combination of halofuginone and sesquiterpene lactone compounds of Artemisia apiacea has a significant synergistic anti-cancer effect. The effect is similar and even superior to the anti-cancer effect of 5-Fu.
A61K 31/357 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant plusieurs atomes d'oxygène dans le même cycle, p. ex. éthers en couronne, guanadrel
A61K 31/517 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinazoline, périmidine
A nano bi-material (A,B), electromagnetic spectrum shifter based on said nano bi-material (A,B) and method to produce said electromagnetic spectrum shifter using said nano bi-material (A,B) are described. In particular, nano bi-material (A,B) based electromagnetic spectrum shifter, e.g. color filters, with a wide range of transmission and color tunability and methods to produce said color filters are presented. The applications in color filters and production of color filters, reflectors and production of reflectors, and electromagnetic spectrum shifters and production of electromagnetic spectrum shifters are provided.
G02B 1/02 - Éléments optiques caractérisés par la substance dont ils sont faitsRevêtements optiques pour éléments optiques faits de cristaux, p. ex. sel gemme, semi-conducteurs
41.
SELECTIVE CANCER TRACKING ERADICATOR AND THE USES THEREOF
The present invention discloses a new modality of photodynamic therapy (PDT) through the design of the present invention's truly dual-functional-PDT and imaging-gadolinium complex (Gd-N) with a molecular formula(I), which can target cancer, cells specifically. The present invention provides a PDT drug that can specifically localize on the anionic cell membrane of cancer cells in which its laser-excited photoemission signal can be monitored without triggering the phototoxic generation of reactive oxygen species-singlet oxygen-prior to due excitation. The present invention also provides the use of Gd-N as a tumor selective PDT photosensitizer modality.
C09K 11/60 - Substances luminescentes, p. ex. électroluminescentes, chimiluminescentes contenant des substances inorganiques luminescentes contenant du fer, du cobalt ou du nickel
C09K 11/77 - Substances luminescentes, p. ex. électroluminescentes, chimiluminescentes contenant des substances inorganiques luminescentes contenant des métaux des terres rares
A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
A method to transfer a layer of harder thin film substrate onto a softer, flexible substrate. In particular, the present invention provides a method to deposit a layer of sapphire thin film on to a softer and flexible substrate e.g. PET, polymers, plastics, paper and fabrics. This combination provides the hardness of sapphire thin film to softer flexible substrates.
Method and apparatus of an eye gaze tracking system, using a generic camera under normal environment,detecting a user's iris and eye corner position associated with at least one eye iris center and at least one eye corner of the user to determine an eye vector associated with the user's gaze direction, processing the eye vector for application of a head pose estimation model arranged to model a head pose of the user so as to devise one or more final gaze points of the user. The system features low cost, simple operation and tolerates large illumination changes.
A non-invasive method for diagnosing performance of a vehicle comprising using at least one 3-axis accelerometer to perform diagnosis of the performance of an internal combustion engine including an engine power loss and one or more flaws associated with the engine mount is provided. The method is also usable for diagnosing deterioration of a suspension system of the vehicle. An apparatus comprising at least one 3-axis accelerometer be used for diagnosing performance of a vehicle is also provided. In one embodiment, the 3-axis accelerometer is embedded in a smart phone. A simple and non-invasive diagnosis of internal combustion engines is provided.
G01M 15/04 - Test des moteurs à combustion interne
F02D 35/02 - Commande non électrique des moteurs en fonction des conditions extérieures ou intérieures aux moteurs, non prévue ailleurs des conditions intérieures
F02D 45/00 - Commande électrique non prévue dans les groupes
F02D 41/14 - Dispositions de circuits pour produire des signaux de commande introduisant des corrections à boucle fermée
45.
MTOR-INDEPENDENT ACTIVATOR OF TFEB FOR AUTOPHAGY ENHANCEMENT AND USES THEREOF
A composition comprising an autophagy enhancement compound is disclosed. Small molecules that are able to enhance autophagy and lysosome biogenesis by activating the gene TFEB which can prevent the accumulation of toxic protein aggregates in treating neurodegenerative diseases are disclosed.
LONG-ACTING GEL COMPOSITION COMPRISING BLOOD SUGAR REDUCING ACTIVE COMPONENT AND CAPABLE OF CONTROLLING AND RELEASING LIPOSOME, AND PREPARATION METHOD THEREFOR
A long-acting hypodermic injection gel composition comprising insulin or exenatide and capable of controlling and releasing liposome, and a preparation method therefor. The control and release composition has very high bioavailability, and continuously performs release according to an effective drug concentration in a period and does not have an excessively high initial rapid release. The preparation method thereof comprises the following steps: mixing insulin or exenatide with lipid and a water dispersion medium, and then mixing the mixture with gel solutions such as poloxamer (such as F127 or P123) and/or a gelatin and a hyaluronic acid (HA), so as to form a protective layer on each lipid micrometer capsule and nanocapsule and deliver the drugs by means of intramuscular injection, abdominal injection or hypodermic injection, so that one injection can provide an effective period of 2 to 7 days, thereby reducing side effects of pains and stimulations.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 47/30 - Composés macromoléculaires organiques ou inorganiques, p. ex. polyphosphates inorganiques
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
47.
GAIT MEASUREMENT WITH 3-AXES ACCELEROMETER/GYRO IN MOBILE DEVICES
A method of gait measurement using tri-axial accelerometer/gyro in mobile devices for monitoring and improving the physical movement of a moving subject, comprising: using a tri-axial accelerometer to formulate: a signature based on measurements of walking, heaving and lateral movements of said subject; and a quantitative indicator indicating the power level dispensed by said subject to keep balance during motion.
A61B 5/11 - Mesure du mouvement du corps entier ou de parties de celui-ci, p. ex. tremblement de la tête ou des mains ou mobilité d'un membre
G01C 23/00 - Instruments combinés indiquant plus d’une valeur de navigation, p. ex. pour l’aviationDispositifs de mesure combinés pour mesurer plusieurs variables du mouvement, p. ex. la distance, la vitesse ou l’accélération
48.
NEW TRIPTOLIDE DERIVATIVES AND PREPARATION METHOD AND USE THEREOF
Disclosed in the present invention are triptolide-nucleic acid aptamer derivatives, and a preparation method and use thereof. The structure of the triptolide-nucleic acid aptamer derivatives is as shown by formula I, wherein the definitions of R1-R7, G, A, B, M, Z and X are as described in the description. The present invention uses a nucleic acid aptamer and triptolide or modifications thereof as the starting materials, and introduces a linking group A at the C-14 hydroxyl groups, epoxy groups and five-membered ring lactones in triptolide, then connects it to a nucleic acid aptamer B, and obtains the triptolide-nucleic acid aptamer derivatives. The triptolide-nucleic acid aptamer derivatives of the present invention have the characteristics of good targeting, a high anticancer activity, low toxicity and side effects, good water solubility and high bioavailability, and the preparation method of the present invention is scientific and reasonable and has a controllable quality and good repeatability, and is thereby suitable for production.
C07J 73/00 - Stéroïdes ayant le squelette du cyclopenta[a]hydrophénanthrène modifié par substitution d'un ou deux atomes de carbone par des hétéro-atomes
C12N 15/115 - Aptamères, c.-à-d. acides nucléiques liant spécifiquement une molécule cible avec une haute affinité sans s'y hybrider
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (USA)
Inventeur(s)
Zhang, Hongjie
Soejarto, Djaja D.
Fong, Harry H.S.
Abrégé
This invention provides maytansinoids having improved tumor inhibition activity, In particular, the present invention pro vides a method of treatment of cancer, in particular colon cancer, using maytansinoid compounds having two fused macrocyclic rings.
A61K 31/535 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p. ex. 1,2-oxazines
C07J 17/00 - Stéroïdes normaux contenant du carbone, de l'hydrogène, un halogène, ou de l'oxygène, ayant un hétérocycle contenant de l'oxygène non condensé avec le squelette du cyclopenta[a]hydrophénanthrène
A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
A method of extracting neural stem cells from a living subject, comprising the steps of introducing magnetic nanoparticles into the subject, targeting the neural stem cells with the magnetic nanoparticles to form magnetic nanoparticle-targeted cells, isolating the magnetic nanoparticle-targeted cells, extracting the magnetic nanoparticles-targeted cells from the subject.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
C07K 7/64 - Peptides cycliques ne comportant que des liaisons peptidiques normales
C07K 7/50 - Peptides cycliques contenant au moins une liaison peptidique anormale
C07C 229/28 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant saturé et contenant des cycles
C07C 229/46 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino ou carboxyle liés à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons du même squelette carboné
THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (Chine)
HONG KONG BAPTIST UNIVERSITY (Chine)
MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY (Chine)
Inventeur(s)
Liang, Chun
Jiang, Zhihong
Wang, Ziyi
Yu, Zhiling
Wang, Jingrong
Bai, Liping
Abrégé
A method for treating cancer by using an agent which is capable of inhibiting the functionality of the MCM complex, a heterohexameric ring formed from six subunits, in the process of DNA replication and a method of screening for such agents by detecting the locations and functions of the MCM subunits, such as hMcm2 and hMcm6, in cells treated with candidate compounds.
A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (Chine)
HONG KONG BAPTIST UNIVERSITY (Chine)
MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY (Chine)
Inventeur(s)
Liang, Chun
Jiang, Zhihong
Wang, Ziyi
Yu, Zhiling
Wang, Jingrong
Bai, Liping
Abrégé
A method for treating cancer by using an agent which is capable of inhibiting the functionality of the MCM complex, a heterohexameric ring formed from six subunits, in the process of DNA replication and a method of screening for such agents by detecting the locations and functions of the MCM subunits, such as hMcm2 and hMcm6, in cells treated with candidate compounds.
A61K 31/56 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
A61K 47/30 - Composés macromoléculaires organiques ou inorganiques, p. ex. polyphosphates inorganiques
THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (Chine)
HONG KONG BAPTIST UNIVERSITY (Chine)
MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY (Chine)
Inventeur(s)
Wang, Ziyi
Liang, Chun
Jiang, Zhihong
Yu, Zhiling
Wang, Jingrong
Bai, Liping
Abrégé
A method of screening for an anticancer compound is provided. The method comprised the steps: (a) contacting a candidate compound with a population of cells and (b) detecting the amount of MCM subunits located in the nucleus as compared that in the cytoplasm or detecting the physical interactions of the MCM subunits.
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables
C12Q 1/34 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une hydrolase
G01N 33/48 - Matériau biologique, p. ex. sang, urineHémocytomètres
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
56.
METHODS AND APPARATUS FOR SMART HEALTHCARE DECISION ANALYTICS AND SUPPORT
The present invention discloses method s and apparatus for developing, analyzing, investigating, and advising healthcare and well-being related decisions. In particular, the present invention relates to the architecture of systems in either stand-al one or distributed/collaborative/pervasive settings, the components of the systems and their underlying processes and couplings, the computational techniques built into the method s, input data sources integrated into and output results produced and distributed by the systems, as well as the apparatus for carrying out the corresponding user interaction, data access and collection, data integration and processing, data-driven inferences and simulation, intelligent computations, decision analytics, and decision support to generating solutions to various healthcare analytics and decision-making problems. This invention al so rel ates to two working illustrations of the method s and apparatus that present the embodiment illustrations of the present invention.
A novel multilayer flexible metamaterial that can work at near infrared (NIR) regime that can be fabricated on transparent PET substrate using flip chip transfer (FCT) technique. An embodiment of the present invention also provides novel NIR metamaterial device that can be transformed into various shapes by bending the PET substrate, wherein said metamaterial device is tunable via physical manipulation of its flexible substrate with no requirement to change the material composition of the substrate. The flexibility allows the novel NIR metamaterial device to bend and stretch, which can alter the device structure. Since the resonant frequency of each device is a function of the device structure, the resonant frequency can be tuned by the bend and stretch of the substrate. Another embodiment of the present invention further provides novel tunable sensors and emitters using such flexible metamaterials and devices.
B32B 3/16 - Produits stratifiés comprenant une couche ayant des discontinuités ou des rugosités externes ou internes, ou une couche de forme non planeProduits stratifiés comprenant une couche ayant des particularités au niveau de sa forme caractérisés par une couche discontinue, c.-à-d. soit continue et percée de trous, soit réellement constituée d'éléments individuels caractérisés par une couche de surface formée d'éléments individuels fixés à un "dos" flexible
G02B 1/00 - Éléments optiques caractérisés par la substance dont ils sont faitsRevêtements optiques pour éléments optiques
58.
FABRICATION OF HIGHLY FLEXIBLE NEAR-INFRARED METAMATERIALS
A method and apparatus of fabrication of a multilayer flexible metamaterial can be fabricated using flip chip transfer (FCT) technique. This technique is different from other similar techniques such as metal lift off process, which fabricates the nanostructures directly onto the flexible substrate or nanometer printing technique. It is a solution-free FCT technique using double-side optical adhesive as the intermediate transfer layer and a tri-layer metamaterial nanostructures on a rigid substrate can be transferred onto adhesive first. Another embodiment of the present invention is the fabrication method and apparatus that allows the transfer of the metamaterial from a rigid substrate such as glass, quartz and metals onto a flexible substrate such as plastic or polymer film. Thus, a flexible metamaterial can be fabricated independent of the original substrate used.
H01Q 15/00 - Dispositifs pour la réflexion, la réfraction, la diffraction ou la polarisation des ondes rayonnées par une antenne, p. ex. dispositifs quasi optiques
Disclosed is a composition comprising compounds of formulae (I-V) or the salts thereof and the pharmaceutically-acceptable carrier, which is used to treat autophagy-associated diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease, etc. Additionally, a method of treating these diseases, as well as the use of said compounds in preparing composition are also disclosed.
A61K 31/435 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle
C07D 491/22 - Composés hétérocycliques contenant dans le système cyclique condensé, à la fois un ou plusieurs cycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle, et un ou plusieurs cycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus dans les groupes , , ou dans lesquels le système condensé contient au moins quatre hétérocycles
60.
AUTOMATIC AND SEMI-AUTOMATIC IMAGE CLASSIFICATION, ANNOTATION AND TAGGING THROUGH THE USE OF IMAGE ACQUISITION PARAMETERS AND METADATA
A method for characterizing image contents automatically or semi-automatically using image acquisition parameters and metadata is presented. The method establishes probabilistic and deterministic relationships between different types of metadata and the semantic attributes and contents of images. It furnishes a mechanism that enables the automatic and semi-automatic classification, annotation, tagging, indexing, searching, identification or retrieval of images based on their contents, semantic properties and metadata characteristics. The method uses, but is not limited to, image capture metadata such as focal length, exposure time, relative aperture, flash information, ISO setting, angle of view, subject distance, timestamp, GPS information as well as other forms of metadata, including but not limited to, captions, keywords, headings, tags, comments, remarks, titles which may be automatically, semi-automatically, or manually generated. The present invention can be applied to image databases, web searching, personal search, community search, broad-based or vertical search engines for internet, intranet, extranet or other usages.
G06F 17/30 - Recherche documentaire; Structures de bases de données à cet effet
G06K 9/00 - Méthodes ou dispositions pour la lecture ou la reconnaissance de caractères imprimés ou écrits ou pour la reconnaissance de formes, p.ex. d'empreintes digitales
brevets
